From the Guidelines

GLP-1 is not currently a standard treatment for Type 1 Diabetes Mellitus, but it is being studied as a potential adjunct therapy to insulin.

GLP-1 receptor agonists, such as liraglutide, have shown benefit in patients with type 1 diabetes by improving hemoglobin A1c levels and reducing body weight 1.
However, the use of GLP-1 receptor agonists in type 1 diabetes is associated with increased adverse events, including hypoglycemia and hyperglycemia with ketosis 1.
The study on liraglutide in type 1 diabetes showed that hemoglobin A1c levels improved by 0.34 to 0.54 percentage point from a mean baseline of 8.2% with once-daily injections of liraglutide (1.8,1.2, or 0.6 mg) added to insulin therapy 1.
Body weight reduction was 2.2 to 4.9 kg greater with liraglutide than placebo, but hypoglycemia rates increased by 20% to 30% 1.
Due to the potential risks and lack of standardization, GLP-1 receptor agonists should be used with caution in type 1 diabetes, and only under the guidance of a healthcare professional.

Patients with type 1 diabetes who are considering GLP-1 receptor agonists should be closely monitored for signs of hypoglycemia and hyperglycemia with ketosis.
The use of GLP-1 receptor agonists in type 1 diabetes is still investigational and not currently approved by the U.S. Food and Drug Administration.

From the Research

GLP-1 receptor agonists have been studied as a potential treatment option for type 1 diabetes mellitus (T1DM) due to their ability to reduce hemoglobin A1c (A1C) levels, promote weight loss, and decrease insulin doses without increasing the risk of hypoglycemia 2, 3.
The mechanism of action of GLP-1 receptor agonists in T1DM involves glucose-dependent insulin secretion, reduced glucagon secretion, increased satiety, and delayed gastric emptying, which can help improve glycemic control and reduce insulin requirements 2, 3.
Studies have shown that GLP-1 receptor agonists such as exenatide and liraglutide can be effective in reducing A1C levels, body weight, and insulin doses in patients with T1DM, with minimal adverse effects 2, 3.

Patients with T1DM who may benefit from GLP-1 receptor agonist therapy include those experiencing adverse effects from insulin, those not at their A1C goal due to hypoglycemia, and those who may benefit from weight loss 2, 3.
Patients with detectable C-peptide and/or those who are overweight or cannot achieve glycemic goals without hypoglycemia may also benefit from GLP-1 receptor agonist therapy 3.
The use of GLP-1 receptor agonists as an adjunct to automated insulin delivery systems may provide additional benefits in terms of glycemic control and metabolic outcomes without increasing the risk of severe hypoglycemia or diabetic ketoacidosis 4.

GLP-1 receptor agonists have been shown to be well-tolerated in patients with T1DM, with minimal adverse effects, mostly gastrointestinal in nature, which are mild and transient 2, 3.
The risk of hypoglycemia with GLP-1 receptor agonist therapy is not significantly increased, making it a safe option for patients with T1DM 2, 3, 4.
Further studies are needed to evaluate the long-term efficacy and safety of GLP-1 receptor agonists in patients with T1DM, particularly in terms of their impact on microvascular and macrovascular complications 3, 5, 6.